Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Kai Qing,Zhen Jin,Zizhen Xu,Wenfang Wang,Xiaoyang Li,Yunxiang Zhang,Lining Wang,Hongming Zhu,Rufang Xiang,Shishuang Wu,Ran Li,Ge Jiang,Kai Xue,Junmin Li

Chemotherapy（2022）

引用 2|浏览22

暂无评分

摘要

In non-GCB DLBCL cells, NF-κB downregulates PRDM1 and thereby promotes MDR1 transcription by terminating PRDM1-induced transcriptional inhibition of MDR1. Such a mechanism may explain the reason for disease recurrence in non-GCB DLBCL after R-CHOP or combined CHOP with bortezomib treatment. Our findings may provide a potential therapeutic strategy for reducing drug resistance in patients with DLBCL.

查看译文

关键词

Doxorubicin,Drug resistance,NF-κB,Non-Hodgkin’s lymphoma,PRDM1 gene

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要